KFDA cautions adverse reactions in ticlopidine HCl therapy

Published: 2002-07-30 06:58:00

Updated: 2002-07-30 06:58:00

The Korea Food and Drug Administration (KFDA) said it recommended the local doctors to conduct the regular hematology and liver functions tests in patients receiving ticlopidine HCl preparations (41 pharmaceutical firms, 61 licensed items), in line with the recent Japanese health ministrys measur...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK